- Home
- ACAD vs VTMX Comparison
ACAD vs VTMX Comparison
Compare ACAD & VTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- VTMX
- Stock Information
- Founded
- ACAD 1993
- VTMX 1998
- Country
- ACAD United States
- VTMX Mexico
- Employees
- ACAD N/A
- VTMX N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- VTMX
- Sector
- ACAD Health Care
- VTMX
- Exchange
- ACAD Nasdaq
- VTMX Nasdaq
- Market Cap
- ACAD 2.5B
- VTMX 2.3B
- IPO Year
- ACAD 2004
- VTMX 2023
- Fundamental
- Price
- ACAD $17.44
- VTMX $27.82
- Analyst Decision
- ACAD Buy
- VTMX Sell
- Analyst Count
- ACAD 15
- VTMX 2
- Target Price
- ACAD $24.21
- VTMX $27.50
- AVG Volume (30 Days)
- ACAD 1.8M
- VTMX 275.4K
- Earning Date
- ACAD 05-07-2025
- VTMX 04-23-2025
- Dividend Yield
- ACAD N/A
- VTMX 2.55%
- EPS Growth
- ACAD N/A
- VTMX N/A
- EPS
- ACAD 1.37
- VTMX 0.13
- Revenue
- ACAD $996,283,000.00
- VTMX $258,927,122.00
- Revenue This Year
- ACAD $13.07
- VTMX $18.81
- Revenue Next Year
- ACAD $10.06
- VTMX $11.83
- P/E Ratio
- ACAD $12.74
- VTMX $20.16
- Revenue Growth
- ACAD 22.42
- VTMX 15.06
- 52 Week Low
- ACAD $13.40
- VTMX $21.30
- 52 Week High
- ACAD $20.68
- VTMX $37.92
- Technical
- Relative Strength Index (RSI)
- ACAD 67.70
- VTMX 68.47
- Support Level
- ACAD $14.45
- VTMX $27.05
- Resistance Level
- ACAD $15.31
- VTMX $27.91
- Average True Range (ATR)
- ACAD 0.69
- VTMX 0.84
- MACD
- ACAD 0.37
- VTMX 0.11
- Stochastic Oscillator
- ACAD 94.92
- VTMX 94.09
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)
Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.